Pathological regression of primary tumour and metastatic lymph nodes following chemotherapy in resectable OG cancer: pooled analysis of two trials.
Journal Information
Full Title: Br J Cancer
Abbreviation: Br J Cancer
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Competing interests DC: Research funding from MedImmune, AstraZeneca, Clovis, Eli Lily, 4SC, Bayer, Celgene, NIHR EME, and Roche; Scientific advisory board for OVIBIO. IC: Research funding from Eli-Lilly, Janssen-Cilag; Honorarium from Eli-Lilly, Eisai, Servier; Advisory board for Eli-Lilly, Bristol Meyers Squibb, MSD, Roche, Merck-Serono, AstraZeneca, OncXerna, Pierre Fabre, Boehringer Ingelheim, Incyte, Astella, GSK, Sotio, Eisai, Daiichi-Sankyo, Taiho, Servier. Naureen Starling: Research funding from Merck, AstraZeneca, BMS, Pfizer; honoraria from Merck-Serono, Novartis, MSD Oncology, Eli Lily, Pierre Fabre, Amgen, GSK, Servier; Advisory board for Pfizer, Servier, AstraZeneca, MSD Oncology, Novartis; travel funding from AstraZeneca, BMS, Eli Lily, Merck, Roche, MSD Oncology. HIG: Advisory board for AstraZeneca and BMS. The remaining authors declare no competing interests."
"Funding This work represents independent research supported by the National Institute for Health and Care Research (NIHR) Biomedical Research Centre at The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London. We would also like to acknowledge CRUK funding for tissue collection and slide scanning."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025